Role of benzylamine oxidase in the cytotoxicity of allylamine toward aortic smooth muscle cells

Robert M. Hysmith, Paul J. Boor

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

In this study we demonstrate that by inhibiting benzylamine oxidase (BzAO) with either semicarbazide or phenelzine, aortic smooth muscle cells (ASMCs) are protected from cytolethal injury by the cardiovascular toxin allylamine. We find that although both semicarbazide and phenelzine inhibit BzAO or ASMCs grown in vitro, phenelzine is the more effective inhibitor. We further demonstrate that although semicarbazide - at concentrations inhibiting BzAO - protects ASMCs from cytolethal concentrations of allylamine, it does not fully protect ASMCs from sublethal injury as assessed by [3H]uridine uptake. In contrast, phenelzine appears to afford complete protection of ASMCs from allylamine injury. Although semicarbazide and phenelzine pretreatment does not interfere with [14C]allylamine uptake by ASMCs, retention time of the 14C-moiety from radiolabeled allylamine is less in pretreated ASMCs. Subcellular distribution studies of ASMCs exposed to [14C]allylamine demonstrate that inhibiting BzAO activity in ASMCs results in marked derangement of the distribution pattern of 14C-moiety in subcellular fractions of ASMCs, with 14C-moiety not localized to mitochondrial/endoplasmic reticulum enriched fractions.

Original languageEnglish (US)
Pages (from-to)133-145
Number of pages13
JournalToxicology
Volume51
Issue number2-3
DOIs
StatePublished - 1988

Fingerprint

Benzylamine Oxidase
Allylamine
Cytotoxicity
Smooth Muscle Myocytes
Muscle
Cells
Phenelzine
Wounds and Injuries
Subcellular Fractions
Uridine
Endoplasmic Reticulum

Keywords

  • Allylamine
  • Benzylamine oxidase (semicarbazide-sensitive amine oxidase)
  • Deprenyl
  • Phenelzine
  • Semicarbazide
  • Vascular smooth muscle cells

ASJC Scopus subject areas

  • Toxicology

Cite this

Role of benzylamine oxidase in the cytotoxicity of allylamine toward aortic smooth muscle cells. / Hysmith, Robert M.; Boor, Paul J.

In: Toxicology, Vol. 51, No. 2-3, 1988, p. 133-145.

Research output: Contribution to journalArticle

Hysmith, Robert M. ; Boor, Paul J. / Role of benzylamine oxidase in the cytotoxicity of allylamine toward aortic smooth muscle cells. In: Toxicology. 1988 ; Vol. 51, No. 2-3. pp. 133-145.
@article{f78ea9b60328424fb0ca849624c6219b,
title = "Role of benzylamine oxidase in the cytotoxicity of allylamine toward aortic smooth muscle cells",
abstract = "In this study we demonstrate that by inhibiting benzylamine oxidase (BzAO) with either semicarbazide or phenelzine, aortic smooth muscle cells (ASMCs) are protected from cytolethal injury by the cardiovascular toxin allylamine. We find that although both semicarbazide and phenelzine inhibit BzAO or ASMCs grown in vitro, phenelzine is the more effective inhibitor. We further demonstrate that although semicarbazide - at concentrations inhibiting BzAO - protects ASMCs from cytolethal concentrations of allylamine, it does not fully protect ASMCs from sublethal injury as assessed by [3H]uridine uptake. In contrast, phenelzine appears to afford complete protection of ASMCs from allylamine injury. Although semicarbazide and phenelzine pretreatment does not interfere with [14C]allylamine uptake by ASMCs, retention time of the 14C-moiety from radiolabeled allylamine is less in pretreated ASMCs. Subcellular distribution studies of ASMCs exposed to [14C]allylamine demonstrate that inhibiting BzAO activity in ASMCs results in marked derangement of the distribution pattern of 14C-moiety in subcellular fractions of ASMCs, with 14C-moiety not localized to mitochondrial/endoplasmic reticulum enriched fractions.",
keywords = "Allylamine, Benzylamine oxidase (semicarbazide-sensitive amine oxidase), Deprenyl, Phenelzine, Semicarbazide, Vascular smooth muscle cells",
author = "Hysmith, {Robert M.} and Boor, {Paul J.}",
year = "1988",
doi = "10.1016/0300-483X(88)90144-8",
language = "English (US)",
volume = "51",
pages = "133--145",
journal = "Toxicology",
issn = "0300-483X",
publisher = "Elsevier Ireland Ltd",
number = "2-3",

}

TY - JOUR

T1 - Role of benzylamine oxidase in the cytotoxicity of allylamine toward aortic smooth muscle cells

AU - Hysmith, Robert M.

AU - Boor, Paul J.

PY - 1988

Y1 - 1988

N2 - In this study we demonstrate that by inhibiting benzylamine oxidase (BzAO) with either semicarbazide or phenelzine, aortic smooth muscle cells (ASMCs) are protected from cytolethal injury by the cardiovascular toxin allylamine. We find that although both semicarbazide and phenelzine inhibit BzAO or ASMCs grown in vitro, phenelzine is the more effective inhibitor. We further demonstrate that although semicarbazide - at concentrations inhibiting BzAO - protects ASMCs from cytolethal concentrations of allylamine, it does not fully protect ASMCs from sublethal injury as assessed by [3H]uridine uptake. In contrast, phenelzine appears to afford complete protection of ASMCs from allylamine injury. Although semicarbazide and phenelzine pretreatment does not interfere with [14C]allylamine uptake by ASMCs, retention time of the 14C-moiety from radiolabeled allylamine is less in pretreated ASMCs. Subcellular distribution studies of ASMCs exposed to [14C]allylamine demonstrate that inhibiting BzAO activity in ASMCs results in marked derangement of the distribution pattern of 14C-moiety in subcellular fractions of ASMCs, with 14C-moiety not localized to mitochondrial/endoplasmic reticulum enriched fractions.

AB - In this study we demonstrate that by inhibiting benzylamine oxidase (BzAO) with either semicarbazide or phenelzine, aortic smooth muscle cells (ASMCs) are protected from cytolethal injury by the cardiovascular toxin allylamine. We find that although both semicarbazide and phenelzine inhibit BzAO or ASMCs grown in vitro, phenelzine is the more effective inhibitor. We further demonstrate that although semicarbazide - at concentrations inhibiting BzAO - protects ASMCs from cytolethal concentrations of allylamine, it does not fully protect ASMCs from sublethal injury as assessed by [3H]uridine uptake. In contrast, phenelzine appears to afford complete protection of ASMCs from allylamine injury. Although semicarbazide and phenelzine pretreatment does not interfere with [14C]allylamine uptake by ASMCs, retention time of the 14C-moiety from radiolabeled allylamine is less in pretreated ASMCs. Subcellular distribution studies of ASMCs exposed to [14C]allylamine demonstrate that inhibiting BzAO activity in ASMCs results in marked derangement of the distribution pattern of 14C-moiety in subcellular fractions of ASMCs, with 14C-moiety not localized to mitochondrial/endoplasmic reticulum enriched fractions.

KW - Allylamine

KW - Benzylamine oxidase (semicarbazide-sensitive amine oxidase)

KW - Deprenyl

KW - Phenelzine

KW - Semicarbazide

KW - Vascular smooth muscle cells

UR - http://www.scopus.com/inward/record.url?scp=0023712143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023712143&partnerID=8YFLogxK

U2 - 10.1016/0300-483X(88)90144-8

DO - 10.1016/0300-483X(88)90144-8

M3 - Article

C2 - 3140421

AN - SCOPUS:0023712143

VL - 51

SP - 133

EP - 145

JO - Toxicology

JF - Toxicology

SN - 0300-483X

IS - 2-3

ER -